Abstract
Objective: We investigated the risk of sudden sensorineural hearing loss (SSNHL) in patients with autoimmune diseases compared with a control group in a population-based study using a National Health Insurance Service National Sample Cohort data from Korea. Methods: We enrolled autoimmune-disease patients who were ≥20 years of age in 2006 into the autoimmune-disease group, and selected a control group with similar demographic characteristics. We tracked the 2 groups from 2006 to 2015 and compared the proportions of patients who developed SSNHL. Results: Of 13,250 patients in the autoimmune-disease group, 145 experienced an SSNHL event (1.09%). Of the 66,250 in the control group, 484 experienced an SSNHL event (0.73%). The SSNHL risk was significantly higher in the autoimmune-disease group than in the control group. SSNHL incidence was significantly higher among patients with antiphospholipid syndrome (APS), multiple sclerosis (MS), rheumatoid arthritis (RA), and connective-tissue diseases including Sjögren syndrome and Behçet disease. In detailed stratified analyses using reinforced additional diagnostic codes, only RA patients had a significantly higher SSNHL incidence than the control group. Conclusion: The association of several autoimmune diseases with SSNHL was evaluated in this large-scale, population-based, big-data study. The risk of SSNHL was significantly higher in patients with APS, MS, RA, and connective-tissue diseases including Sjögren syndrome and Behçet disease than in patients without autoimmune diseases. SSNHL, in particular, was significantly associated with RA according to detailed analyses using reinforced additional diagnostic codes.
References
1.
Abbasi
M
, Yazdi
Z
, Kazemifar
AM
, Bakhsh
ZZ
. Hearing loss in patients with systemic lupus erythematosus
. Glob J Health Sci
. 2013
;5
(5
):102
–6
. 1916-97362.
Atturo
F
, Colangeli
R
, Bandiera
G
, Barbara
M
, Monini
S
. Can unilateral, progressive or sudden hearing loss be immune-mediated in origin?
Acta Otolaryngol
. 2017
;137
(8
):823
–8
. 0001-64893.
Atula
S
, Sinkkonen
ST
, Saat
R
, Sairanen
T
, Atula
T
. Association of multiple sclerosis and sudden sensorineural hearing loss
. Mult Scler J Exp Transl Clin
. 2016
;2
:2055217316652155
. 2055-21734.
Chawki
S
, Aouizerate
J
, Trad
S
, Prinseau
J
, Hanslik
T
. Bilateral sudden sensorineural hearing loss as a presenting feature of systemic lupus erythematosus: case report and brief review of other published cases
. Medicine (Baltimore)
. 2016
;95
(36
):e4345
. 0025-79745.
Compadretti
GC
, Brandolini
C
, Tasca
I
. Sudden sensorineural hearing loss in lupus erythematosus associated with antiphospholipid syndrome: case report and review
. Ann Otol Rhinol Laryngol
. 2005
;114
(3
):214
–8
. 0003-48946.
Di Leo
E
, Coppola
F
, Nettis
E
, Vacca
A
, Quaranta
N
. Late recovery with cyclosporine-A of an auto-immune sudden sensorineural hearing loss
. Acta Otorhinolaryngol Ital
. 2011
;31
:399
–401
.0392-100X7.
Emamifar
A
, Hansen
IM
. An update on hearing impairment in patients with rheumatoid arthritis
. J Otol
. 2018
;13
(1
):1
–4
. 1672-29308.
Galarza-Delgado
DA
, Villegas Gonzalez
MJ
, Riega Torres
J
, Soto-Galindo
GA
, Mendoza Flores
L
, Treviño González
JL
. Early hearing loss detection in rheumatoid arthritis and primary Sjögren syndrome using extended high frequency audiometry
. Clin Rheumatol
. 2018
;37
(2
):367
–73
. 0770-31989.
Greco
A
, Fusconi
M
, Gallo
A
, Marinelli
C
, Macri
GF
, De Vincentiis
M
. Sudden sensorineural hearing loss: an autoimmune disease?
Autoimmun Rev
. 2011
;10
(12
):756
–61
. 1568-997210.
Habets
KL
, Trouw
LA
, Levarht
EW
, Korporaal
SJ
, Habets
PA
, de Groot
P
, et al. Anti-citrullinated protein antibodies contribute to platelet activation in rheumatoid arthritis
. Arthritis Res Ther
. 2015
;17
(1
):209
. 1478-635411.
Hellmann
MA
, Steiner
I
, Mosberg‐Galili
R
. Sudden sensorineural hearing loss in multiple sclerosis: clinical course and possible pathogenesis
. Acta Neurol Scand
. 2011
;124
(4
):245
–9
. 0001-631412.
Jeong
H
, Chang
YS
, Baek
SY
, Kim
SW
, Eun
YH
, Kim
IY
, et al. Evaluation of Audiometric Test Results to Determine Hearing Impairment in Patients with Rheumatoid Arthritis: Analysis of Data from the Korean National Health and Nutrition Examination Survey
. PLoS One
. 2016
;11
(10
):e0164591
. 1932-620313.
Kang
KT
, Young
YH
. Sudden sensorineural hearing loss in a patient with primary antiphospholipid syndrome
. J Laryngol Otol
. 2008
;122
(2
):204
–6
. 0022-215114.
Kikuchi
T
, Yokoe
I
, Masuyama
A
, Maniwa
K
, Tsuruta
S
, Hatanaka
Y
, et al. Behcet’s disease initially presenting with meningitis and sudden hearing loss
. Intern Med
. 2010
;49
(5
):483
–6
. 0918-291815.
Knijff-Dutmer
EA
, Koerts
J
, Nieuwland
R
, Kalsbeek-Batenburg
EM
, van de Laar
MA
. Elevated levels of platelet microparticles are associated with disease activity in rheumatoid arthritis
. Arthritis Rheum
. 2002
;46
(6
):1498
–503
. 0004-359116.
Lee
JM
, Kim
JY
, Bok
J
, Kim
KS
, Choi
JY
, Kim
SH
. Identification of evidence for autoimmune pathology of bilateral sudden sensorineural hearing loss using proteomic analysis
. Clin Immunol
. 2017
;183
:24
–35
. 1521-661617.
Lee
SY
, Kong
IG
, Oh
DJ
, Choi
HG
. Increased risk of sudden sensory neural hearing loss in patients with rheumatoid arthritis: a longitudinal follow-up study using a national sample cohort
. Clin Rheumatol
. 2018
;•••
: 0770-319818.
Lin
C
, Lin
SW
, Weng
SF
, Lin
YS
. Risk of sudden sensorineural hearing loss in patients with systemic lupus erythematosus: a population-based cohort study
. Audiol Neurotol
. 2013
;18
(2
):95
–100
. 1420-303019.
Lobo
FS
, Dossi
MO
, Batista
L
, Shinzato
MM
. Hearing impairment in patients with rheumatoid arthritis: association with anti-citrullinated protein antibodies
. Clin Rheumatol
. 2016
;35
(9
):2327
–32
. 0770-319820.
McCabe
BF
. Autoimmune sensorineural hearing loss
. Ann Otol Rhinol Laryngol
. 1979
;88
(5
):585
–9
. 0003-489421.
McInnes
IB
, Schett
G
. The pathogenesis of rheumatoid arthritis
. N Engl J Med
. 2011
;365
(23
):2205
–19
. 0028-479322.
Melikoglu
MA
, Senel
K
. Sudden hearing loss in a patient with rheumatoid arthritis; a case report and review of the literature
. Acta Reumatol Port
. 2013
;38
:138
–9
.0303-464X23.
Oh
YM
, Oh
DH
, Jeong
SH
, Koo
JW
, Kim
JS
. Sequential bilateral hearing loss in multiple sclerosis
. Ann Otol Rhinol Laryngol
. 2008
;117
(3
):186
–91
. 0003-489424.
Rossini
BA
, Penido
NO
, Munhoz
MS
, Bogaz
EA
, Curi
RS
. Sudden Sensorioneural Hearing Loss and Autoimmune Systemic Diseases
. Int Arch Otorhinolaryngol
. 2017
;21
(03
):213
–23
. 1809-977725.
Tanaka
M
, Tanaka
K
. Sudden hearing loss as the initial symptom in Japanese patients with multiple sclerosis and seropositive neuromyelitis optica spectrum disorders
. J Neuroimmunol
. 2016
;298
:16
–8
. 0165-572826.
Tekin
M
, Acar
GO
, Cam
OH
, Hanege
FM
. Sudden sensorineural hearing loss in a multiple sclerosis case
. North Clin Istanb
. 2014
;1
(2
):109
–13
. 2536-455327.
Wang
JG
, Xie
QB
, Yang
NP
, Yin
G
. Primary antiphospholipid antibody syndrome: a case with bilateral sudden sensorineural hearing loss
. Rheumatol Int
. 2009
;29
(4
):467
–8
. 0172-817228.
Wiles
NM
, Hunt
BJ
, Callanan
V
, Chevretton
EB
. Sudden sensorineural hearing loss and antiphospholipid syndrome
. Haematologica
. 2006
;91
:ECR46
.0390-6078© 2019 S. Karger AG, Basel
2019
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
